← All trials
NCT02802514
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 20, 2016
- Primary completion
- Sep 29, 2017
- Completion date
- Sep 29, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 28
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- GlaxoSmithKlineLead sponsor
- GlaxoSmithKlineStudy director
- Harvard UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.